EXCLUSIVE: Hoth Therapeutics Highlights HT/VA GDNF Data; Says In Head-To-Head Comparison Drug Demonstrated 'Superior Efficacy' Compared With Semaglutide Across Key Metrics

Key Study Highlights:
 Superior Weight Management: In female mice on a high-fat Western diet, GDNF attenuated weight gain by 10-15%, leading to a plateau in the final weeks of treatment—unlike semaglutide, which showed no significant impact. Researchers noted that higher doses or longer durations could amplify GDNF's effects, suggesting even greater potential for sustained weight loss.

Enhanced Glucose Metabolism: GDNF fully normalized fasting glucose and improved overall response to glucose challenges, outperforming semaglutide in females. Baseline improvements were also seen in males, indicating broad metabolic benefits.

Liver and Adipose Health: GDNF reduced liver weight by 20-30% and prevented adipose tissue accumulation in females, surpassing semaglutide's effects. This underscores GDNF's promise in resolving fatty liver disease, a common complication of obesity.

Study Design: Conducted at the Srinivasan Lab with VA support, the 12 week study used CF-1 mice to model human obesity. GDNF was administered subcutaneously with escalating doses (2-12 μg/mouse), compared to semaglutide (12 ng/g/mouse).